Document is current
Any future updates will be listed below
-
Authors
Spiliopoulou, Pavlina https://orcid.org/0000-0002-6486-6319
Janse van Rensburg, Helena J.
Avery, Lisa
Kulasingam, Vathany
Razak, Albiruni
Bedard, Philippe
Hansen, Aaron
Chruscinski, Andrzej
Wang, Ben
Kulikova, Maria
Chen, Rachel
Speers, Vanessa
Nguyen, Alisa
Lee, Jasmine
Coburn, Bryan
Spreafico, Anna
Siu, Lillian L. https://orcid.org/0000-0002-3500-0540
- License Information
-
More Information
Article History
Received: 28 October 2022
Revised: 17 December 2022
Accepted: 30 December 2022
First Online: 20 January 2023
Competing interests
: LLS has consulting/advisory arrangements with Merck, Pfizer, AstraZeneca, Roche, Symphogen, Seattle Genetics, GlaxoSmithKline, Voronoi, Arvinas, Tessa, Navire, Relay, Rubius, Janpix, Daiichi Sanyko, Coherus, Marengo, InteRNA; stock ownership of Agios (spouse); leadership position in Treadwell Therapeutics (spouse); and institution receives clinical trials support from Novartis, Bristol-Myers Squibb, Pfizer, Boerhinger-Ingelheim, GlaxoSmithKline, Roche/Genentech, Karyopharm, AstraZeneca, Merck, Celgene, Astellas, Bayer, Abbvie, Amgen, Symphogen, Intensity Therapeutics, Mirati Therapeutics, Shattucks. AS participated in advisory board for Merck (compensated), Bristol-Myers Squibb (compensated), Oncorus (compensated), Janssen (compensated), Medison & Immunocore (compensated). Also receives Grant/Research support from: Novartis, Bristol-Myers Squibb, Symphogen AstraZeneca/Medimmune, Merck, Bayer, Surface Oncology, Northern Biologics, Janssen Oncology/Johnson & Johnson, Roche, Regeneron, Alkermes, Array Biopharma/Pfizer, GSK, Oncorus, Treadwell, Amgen. VK is a Consultant for Abbott Diagnostics. BC receives in-kind support from Nubiyota and clinical trial support from Sanofi. The rest of the authors declare no competing interests.
: This study was conducted with the approval of University Health Network Oncology Research Ethics Board (CAPCR/UHN REB #: 21–5797) and all patients signed informed consent.
